Skip to content
Search

Latest Stories

England call off Pakistan tour after New Zealand security scare

England call off Pakistan tour after New Zealand security scare

ENGLAND have withdrawn their men's and women's teams from next month's tour of Pakistan, the country's cricket board (ECB) said on Monday (20), three days after New Zealand abandoned their tour of the country amid security concerns.

The England teams were each scheduled to play two Twenty20 international matches on Oct. 13 and 14 in Rawalpindi, with the women's side due to stay on for a three-match one-day international series from Oct. 17-21.


"The ECB Board convened this weekend to discuss these extra England Women's and Men's games in Pakistan and we can confirm that the Board has reluctantly decided to withdraw both teams from the October trip," the ECB said in a statement.

"The mental and physical well-being of our players and support staff remains our highest priority and this is even more critical given the times we are currently living in.

"We know there are increasing concerns about travelling to the region and believe that going ahead will add further pressure to a playing group who have already coped with a long period of operating in restricted COVID environments."

The ECB added that the men's team touring under such conditions would not be ideal preparation for the Twenty20 World Cup next month.

"We understand that this decision will be a significant disappointment to the PCB, who have worked tirelessly to host the return of international cricket in their country," it added.

"We are sincerely sorry for the impact this will have on cricket in Pakistan and emphasise an ongoing commitment to our main touring plans there for 2022."

New Zealand abruptly abandoned their tour of Pakistan on Friday (17) citing a security alert, in a massive blow to the South Asian country's hopes of staging regular international cricket.

The tour was due to get underway with the first of three one-dayers in Rawalpindi on Friday but the New Zealand team did not travel to the stadium.

New Zealand Prime Minister Jacinda Ardern backed New Zealand Cricket's decision to end the tour.

International teams have largely refused to tour Pakistan since an attack by Islamist militants on the Sri Lanka team bus in Lahore in 2009 that killed six policemen and two civilians.

There are fears that New Zealand's decision to go home will keep them away and Australia, who are scheduled to visit in February-March next year, also appear wary.

A Cricket Australia spokesperson said the organisation was monitoring the situation and would "talk with the relevant authorities once more information becomes known".

(Reuters)

More For You

pharmacy

The UK spends just 9 per cent of healthcare budgets on medicines while patients face growing access gaps.

iStock

UK calls for new pharmaceutical investment to strengthen life sciences

Highlights

  • UK life sciences sector contributed £17.6bn GVA in 2021 and supports 126,000 high-skilled jobs.
  • Inward life sciences FDI fell by 58 per cent from £1,897m in 2021 to £795m in 2023.
  • Experts warn NHS underinvestment and NICE pricing rules are deterring innovation and patient access.

Investment gap

Britain is seeking to attract new pharmaceutical investment as part of its plan to strengthen the life sciences sector, Chancellor Rachel Reeves said during meetings in Washington this week. “We do need to make sure that we are an attractive place for pharmaceuticals, and that includes on pricing, but in return for that, we want to see more investment flow to Britain,” Reeves told reporters.

Recent ABPI report, ‘Creating the conditions for investment and growth’, The UK’s pharmaceutical industry is integral to both the country’s health and growth missions, contributing £17.6 billion in direct gross value added (GVA) annually and supporting 126,000 high-skilled jobs across the nation. It also invests more in research and development (R&D) than any other sector. Yet inward life sciences foreign direct investment (FDI) fell by 58per cent, from £1,897 million in 2021 to £795 million in 2023, while pharmaceutical R&D investment in the UK lagged behind global growth trends, costing an estimated £1.3 billion in lost investment in 2023 alone.

Keep ReadingShow less